Paper Details

  1. Home
  2. Paper Details

Targeting the Pro-survival Protein BCL-2 to Prevent Breast Cancer.

Author: BuWen, DhamneSagar, DuYi-Chieh Nancy, HilsenbeckSusan G, JiangWeiyu, KapaliJyoti, KuAmy, LiYi, QinLan, YoungAdelaide

Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Research Support, N.I.H., ExtramuralResearch funding provided by the NIH to external research institutions and researchers.
Research Support, Non-U.S. Gov'tResearch funding provided by government agencies outside the United States.

Overview

This study developed a new murine model of breast cancer and investigated the chemopreventive efficacy of venetoclax. Venetoclax treatment delayed tumor progression, improved survival, and reduced metastasis, suggesting its potential as a chemopreventive agent for breast cancer.
Paper Details　
Original Abstract of the Article :
Current chemopreventive strategies require 3-5 years of continuous treatment and have the concerns of significant side effects; therefore, new chemopreventive agents that require shorter and safer treatments are urgently needed. In this study, we developed a new murine model of breast cancer that mi...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://pubmed.ncbi.nlm.nih.gov/34667127

データ提供：米国国立医学図書館（NLM）

Targeting BCL-2 for Breast Cancer Prevention

The field of [Breast Cancer] research is constantly searching for new and improved ways to prevent this devastating disease. This study investigated the potential of [Venetoclax], a [BCL-2]-specific antagonist, as a [Chemopreventive Agent] for [Breast Cancer]. The researchers used a [Murine Model] of [Breast Cancer] and found that [Venetoclax] effectively delayed tumor progression and improved survival rates.

Prophylactic Treatment with Venetoclax

The study demonstrated that [Venetoclax] can be used prophylactically to prevent [Breast Cancer]. This finding has significant implications for individuals at high risk of developing the disease. It offers a potential alternative to current [Chemopreventive] regimens, which often require prolonged treatment and have associated side effects.

A New Frontier in Breast Cancer Prevention

This research opens up new avenues for [Breast Cancer] prevention. It's like discovering a hidden oasis in the vast desert of cancer research – offering hope and potential solutions for a disease that affects so many. This research suggests that targeting the [Pro-survival Protein BCL-2] could be a promising strategy for preventing [Breast Cancer] and improving patient outcomes.

Dr.Camel's Conclusion

The study suggests that prophylactic treatment with venetoclax, a BCL2-specific antagonist, could be a promising strategy for preventing breast cancer initiated by a mutated and activated PIK3CA, the most common breast oncogene.

Date :
  1. Date Completed 2022-04-04
  2. Date Revised 2022-07-16
Further Info :

Pubmed ID

34667127

DOI: Digital Object Identifier

NIHMS1751278

Related Literature

Article Analysis
・Side Effects of venetoclax
SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.